categories: CD and Related Antigens (Human)

Mouse Monoclonal to CD279 / PD-1

EH12.2H7 (IgG1)

Product No.	Form	Quantity	Price
11-176-C025	purified	0.025 mg	choose region
11-176-C100	purified	0.1 mg	choose region
12-176-C100	low endotoxin	0.1 mg	choose region
1F-176-T100	FITC	100 tests	choose region
A4-176-T100	Alexa Fluor® 488	100 tests	choose region
1P-176-T025	PE	25 tests	choose region
1P-176-T100	PE	100 tests	choose region
1A-176-T100	APC	100 tests	choose region
A6-176-T100	Alexa Fluor® 647	100 tests	choose region

- In stock! Ready for immediate despatch

- Manufacture on order

Background

CD279 / PD-1 (programmed cell death 1), a transmembrane protein of CD28/CTLA-4 family. It is expressed inducibly mainly on activated T, B, and myeloid cells and plays a role in maintaining peripheral self-tolerance. Binding to its receptors CD273 and CD274 is associated with inhibition of T cell proliferation and induction of their anergy. It is also expressed during thymic development. Some variants of CD279 are associated with susceptibility to systemic lupus erythematosus, type 1 diabetes, and rheumatoid arthritis.

Entrez Gene: 2q37.3

Specificity

The mouse monoclonal antibody EH12.2H7 recognizes CD279 / PD-1 (programmed cell death 1), a 55 kDa type I transmembrane protein expressed above all during T cell development, on activated T cells, activated B cells, and activated monocytes.

Regulatory Status

RUO

Species Reactivity: Human Non-Human Primates Negative Species:	Applications: Flow Cytometry Immunohistochemistry (frozen sections) Functional Application blocking Usage note: Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.	Product Specific References Zhou J, Cheung AK, Liu H, Tan Z, Tang X, Kang Y, Du Y, Wang H, Liu L, Chen Z: Potentiating functional antigen-specific CD8⁺ T cell immunity by a novel PD1 isoform-based fusion DNA vaccine. Mol Ther. 2013 Jul;21(7):1445-55. [Abstract] [Full Text] Xu Y, Weatherall C, Bailey M, Alcantara S, De Rose R, Estaquier J, Wilson K, Suzuki K, Corbeil J, Cooper DA, Kent SJ, Kelleher AD, Zaunders J: Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques. J Virol. 2013 Apr;87(7):3760-73. [Abstract] [Full Text] Bedoret D, Singh AK, Shaw V, Hoyte EG, Hamilton R, DeKruyff RH, Schneider LC, Nadeau KC, Umetsu DT: Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab. Mucosal Immunol. 2012 May;5(3):267-76. [Abstract] [Full Text] Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, Rosenberg SA: PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014 May;124(5):2246-59. [Abstract] [Full Text] *Haile ST, Dalal SP, Clements V, Tamada K, Ostrand-Rosenberg S: Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. J Immunol. 2013 Sep 1;191(5):2829-36. [Abstract] [Full Text]

Species Reactivity:

Human
Non-Human Primates

Negative Species:

Applications:

Flow Cytometry
Immunohistochemistry (frozen sections)
Functional Application
blocking

Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

Product Specific References

*Zhou J, Cheung AK, Liu H, Tan Z, Tang X, Kang Y, Du Y, Wang H, Liu L, Chen Z: Potentiating functional antigen-specific CD8⁺ T cell immunity by a novel PD1 isoform-based fusion DNA vaccine. Mol Ther. 2013 Jul;21(7):1445-55. [Abstract] [Full Text]

*Xu Y, Weatherall C, Bailey M, Alcantara S, De Rose R, Estaquier J, Wilson K, Suzuki K, Corbeil J, Cooper DA, Kent SJ, Kelleher AD, Zaunders J: Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques. J Virol. 2013 Apr;87(7):3760-73. [Abstract] [Full Text]

*Bedoret D, Singh AK, Shaw V, Hoyte EG, Hamilton R, DeKruyff RH, Schneider LC, Nadeau KC, Umetsu DT: Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab. Mucosal Immunol. 2012 May;5(3):267-76. [Abstract] [Full Text]

*Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, Rosenberg SA: PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014 May;124(5):2246-59. [Abstract] [Full Text]

*Haile ST, Dalal SP, Clements V, Tamada K, Ostrand-Rosenberg S: Soluble CD80 restores T cell activation and overcomes tumor cell programmed death ligand 1-mediated immune suppression. J Immunol. 2013 Sep 1;191(5):2829-36. [Abstract] [Full Text]

For research use only. Not for drug, diagnostic or other use.

Example Data

Fig. 1. Surface staining of PHA-activated (3 days) human PBMC with anti-CD279 (EH12.2H7) PE.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO´s term and conditions which are available at www.exbio.cz.

Alexa Fluor®, Pacific Blue™ and Pacific Orange™ are registred trademarks of Molecular Probes Inc., Eugene, OR, USA. (licence label)

DyLight® is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

Cy™ and CyDye™ are registered trademarks of GE Healthcare.

PRODUCTS